SCHEMBL270103

SCHEMBL270103

Cc1ccc(C=NNC(=O)c2cc(N3CCCCC3)ccc2NC(=O)c2cccc(CN3CCC(O)CC3)c2)cc1C

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 4/20 0.48
ACKR3 P25106 4/20 0.44
KDR P35968 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
F10 P00742 1/20 0.38
SLC34A1 Q06495 1/20 0.38
SLC34A3 Q8N130 1/20 0.38
SLC20A1 Q8WUM9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270102 1.00 SLC34A2 (0.48) SLC34A2ACKR3KDRCA1CA2
SCHEMBL266819 0.93 SLC34A2 (0.47) SLC34A2ACKR3CA1CA2CA7
SCHEMBL266820 0.93 SLC34A2 (0.47) SLC34A2ACKR3CA1CA2CA7
SCHEMBL267411 0.90 CA1 (0.40) SLC34A2ACKR3CA1CA2CA7
SCHEMBL267412 0.90 CA1 (0.40) SLC34A2ACKR3CA1CA2CA7
SCHEMBL269317 0.90 SLC34A2 (0.48) SLC34A2ACKR3CA1CA2CA7
SCHEMBL269316 0.90 SLC34A2 (0.48) SLC34A2ACKR3CA1CA2CA7
SCHEMBL267910 0.89 MAPT (0.47) SLC34A2ACKR3MAPTCYP2C9
SCHEMBL267911 0.89 MAPT (0.47) SLC34A2ACKR3MAPTCYP2C9
SCHEMBL267467 0.89 SLC34A2 (0.49) SLC34A2ACKR3CYP1A2CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885ACKR3 751/4885KDR 694/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885ACKR3 809/4885KDR 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.